VALENCIA, Calif. – Biopharmaceutical company MannKind Corp. is collaborating with diabetes digital health company One Drop to study the use of inhaled insulin with the One Drop digital diabetes care platform.
The A-ONE randomized controlled study will investigate the use of Afrezza inhaled insulin and One Drop’s integrated digital diabetes care platform.
“This study is intended to evaluate whether combining a solutions-oriented digital disease management platform like One Drop with an innovative drug like Afrezza will provide patients with an improved ability to manage their diabetes,” said Dr. Raymond Urbanski, chief medical officer of MannKind Corp., in a statement.
Study participants with Type 2 diabetes will be randomized to one of two treatment arms: Afrezza with One Drop | Premium or One Drop | Premium alone. Changes in hemoglobin A1C, quality of life, self-care, treatment satisfaction and other metrics will be assessed.
“We know each piece of the puzzle works, and now we want to see how well they work together,” said Dr. Chandra Osborn, vice president of health and behavioral informatics at One Drop, in a statement. “The combination of One Drop with inhaled insulin could offer consumers, health care providers and payers a potentially powerful solution with unprecedented benefits.”